Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,109.14
(
-0.24%
)
US TECH 100
25,918.50
(
-0.14%
)
Dow Jones
49,442.56
(
-0.01%
)
Brent Oil
91.01
(
0.36%
)
Bitcoin
75,835.51
(
-0.08%
)
News Focus
News Focus
Post# of 517460
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Talon38

Send PM Follow Ignore
Followers 29
Posts 2263
Boards Moderated 0
Alias Born 12/13/2016

Talon38

Re: tredenwater2 post# 362252

Friday, 06/03/2022 1:39:43 PM

Friday, June 03, 2022 1:39:43 PM

Post# of 517460
Tred and Nidan....one of the problems of AVXL's valuation is the current WS view of the companies involved with the Alzheimer's drugs. When looking at the history of Biogen, Cassava and several others, investors are becoming conservative and demanding "show me" in this sector of biotech. A measured approach like Anavex's frustrates traders, but will pay investors in the course of 2-73/3-71's development.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News